Therapeutic inadequacy in spite of bioequivalency on replacing Fluctine® with Fluocim®

Jacqueline Albrecht, MD, Solothurn
Rolf H. Adler, Professor of Medicine, Medical Division Lory, University of Berne Medical School

At the beginning of October 1996, a 61-year-old woman with sleeping problems, loss of appetite, lack of drive and interest, difficulties with concentration and anxiety was prescribed 20 mg of Fluctine® daily. After 14 days the symptoms had subsided and she began to take up hobbies she had neglected for years. In 1998 physician and patient decided to change to 20 mg of the generic Fluocim® (daily dose costing CHF 2.75 rather than CHF 3.70). Eighteen days later the physician was surprised to find that the patient showed symptoms similar to those of October 1996. Convinced that the regression could not be due to the generic, the physician suggested keeping it on for another 14 days. Two weeks later the patient’s condition was unchanged. Fluocim® was withdrawn and Fluctine® reinstated. After 14 days she was again symptom-free and has remained so for 14 months. A similar observation was reported by Hovaquimian[1].

The authors conclude on the need to check the patient’s blood levels the next time such a case arises.

References

The many reasons why you should choose SMW to publish your research

*What Swiss Medical Weekly has to offer:*  
- SMW's impact factor has been steadily rising, to the current 1.537  
- Open access to the publication via the Internet, therefore wide audience and impact  
- Rapid listing in Medline  
- LinkOut-button from PubMed with link to the full text website http://www.smw.ch (direct link from each SMW record in PubMed)  
- No-nonsense submission – you submit a single copy of your manuscript by e-mail attachment  
- Peer review based on a broad spectrum of international academic referees  
- Assistance of our professional statistician for every article with statistical analyses  
- Fast peer review, by e-mail exchange with the referees  
- Prompt decisions based on weekly conferences of the Editorial Board  
- Prompt notification on the status of your manuscript by e-mail  
- Professional English copy editing  
- No page charges and attractive colour offprints at no extra cost

*Editorial Board*  
Prof. Jean-Michel Dayer, Geneva  
Prof. Peter Gehr, Berne  
Prof. André P. Perruchoud, Basel  
Prof. Andreas Schaffner, Zurich  
( Editor in chief)  
Prof. Werner Straub, Berne  
Prof. Ludwig von Segesser, Lausanne

*International Advisory Committee*  
Prof. K. E. Juhani Airaksinen, Turku, Finland  
Prof. Anthony Bayes de Luna, Barcelona, Spain  
Prof. Hubert E. Blum, Freiburg, Germany  
Prof. Walter E. Haefeli, Heidelberg, Germany  
Prof. Nino Kuenzli, Los Angeles, USA  
Prof. René Lutter, Amsterdam, The Netherlands  
Prof. Claude Martin, Marseille, France  
Prof. Josef Patsch, Innsbruck, Austria  
Prof. Luigi Tavazzi, Pavia, Italy

We evaluate manuscripts of broad clinical interest from all specialities, including experimental medicine and clinical investigation.

We look forward to receiving your paper!

Guidelines for authors:  
http://www.smw.ch/set_authors.html

---

*Impact factor Swiss Medical Weekly*

![Impact factor chart](chart.png)

*All manuscripts should be sent in electronic form, to:*  
EMH Swiss Medical Publishers Ltd.  
SMW Editorial Secretariat  
Farnburgerstrasse 8  
CH-4132 Muttenz

Manuscripts: submission@smw.ch  
Letters to the editor: letters@smw.ch  
Editorial Board: red@smw.ch  
Internet: http://www.smw.ch